investors.abcellera.comAbCellera Biologics Inc. - Investor
investors.abcellera.com Profile
Investors.abcellera.com is a subdomain of abcellera.com, which was created on 2012-10-19,making it 12 years ago.
Description：AbCellera's AI-powered platform searches, decodes, and analyzes natural immune systems to find antibodies its partners can develop...
Discover investors.abcellera.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investors.abcellera.com Information
| HomePage size: 70.968 KB |
| Page Load Time: 0.326326 Seconds |
| Website IP Address: 162.159.130.11 |
investors.abcellera.com Similar Website
| Synopsys, Inc. | Investor Relations & Investor Resources |
| Masonite International Corp. - Investor Relations - Investor Relations |
| Home - Biologics by McKesson |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| MindChamps PreSchool Limited - Investor Relations: Investor Relations |
| USD Partners Investor Center - Investor Center |
| Home - Ayala Land Investor Relations : Ayala Land Investor Relations |
| Equitable Bank Investor Relations - Investor Relations |
| Ameriprise Financial Investor Relations | Investor Relations |
| Biosimilars Conferences | Biologics Conferences | Biosimilars 2024 | Pharmaceutical Conferences | Bi |
| Biologics CDMO | Catalent Biologics |
| Skye Biologics Inc Mission Statement Employees and |
investors.abcellera.com PopUrls
| AbCellera Biologics Inc. - Investor Relations https://investors.abcellera.com/overview/default.aspx |
| Events & Presentations https://investors.abcellera.com/events/default.aspx |
| Stock Info https://investors.abcellera.com/stock-info/default.aspx |
| News Releases https://investors.abcellera.com/news/default.aspx |
| Financials - SEC Filings https://investors.abcellera.com/financials/sec-filings/default.aspx |
| AbCellera Biologics Inc. - Contact - FAQ https://investors.abcellera.com/contact/faq/default.aspx |
| Privacy Policy https://investors.abcellera.com/Privacy-Policy/ |
| Governance - Committee Composition https://investors.abcellera.com/governance/committee-composition/default.aspx |
| Governance Documents https://investors.abcellera.com/governance/governance-documents/default.aspx |
| AbCellera Reports Full Year 2022 Business Results https://investors.abcellera.com/news/news-releases/2023/AbCellera-Reports-Full-Year-2022-Business-Results/default.aspx |
| AbCellera Reports Full Year 2023 Business Results https://investors.abcellera.com/news/news-releases/2024/AbCellera-Reports-Full-Year-2023-Business-Results/default.aspx |
| AbCellera Reports Full Year 2021 Business Results https://investors.abcellera.com/news/news-releases/2022/AbCellera-Reports-Full-Year-2021-Business-Results/default.aspx |
| AbCellera Biologics Inc. - Financials - Quarterly Results https://investors.abcellera.com/financials/quarterly-results/default.aspx |
| AbCellera Reports Q3 2023 Business Results https://investors.abcellera.com/news/news-releases/2023/AbCellera-Reports-Q3-2023-Business-Results/default.aspx |
| AbCellera Reports Q3 2022 Business Results https://investors.abcellera.com/news/news-releases/2022/AbCellera-Reports-Q3-2022-Business-Results/default.aspx |
investors.abcellera.com Httpheader
| Date: Thu, 16 May 2024 16:57:04 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 884ce7996cd12f47-LAX |
| CF-Cache-Status: REVALIDATED |
| Cache-Control: public, max-age=10, stale-if-error=86400, stale-while-revalidate=86400 |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Vary: Accept-Encoding |
| X-Content-Type-Options: nosniff |
| X-XSS-Protection: 0 |
| Server: |
investors.abcellera.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-type"/ |
| content="RevealTrans(Duration=0,Transition=0)" http-equiv="Page-Enter"/ |
| content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/ |
| content="width=device-width, initial-scale=1" name="viewport"/ |
| content="FOXSzxol45tfEbuLxTiSQDslv_U8iuG3JAiUnLu6SFI" name="google-site-verification"/ |
| content="uACdDobO69eyDIx1oEa65YFwZYtVMFy3j6S309IVO0g" name="google-site-verification"/ |
| content="sCvOw0Fej1Zhdl3PpCgbR_GaEZyqzR4OQ1Kkw9ZEwnM" name="google-site-verification"/ |
| content="AbCellera's AI-powered platform searches, decodes, and analyzes natural immune systems to find antibodies its partners can develop into drugs." |
investors.abcellera.com Html To Plain Text
Relations News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials Quarterly Results SEC Filings Governance Governance Documents Management Board of Directors Committee Composition Contact FAQ Request Info Email Alerts Site Search Search query News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Analyst Coverage Financials Quarterly Results SEC Filings Governance Governance Documents Management Board of Directors Committee Composition Contact FAQ Request Info Email Alerts Search query Investor Relations Corporate Overview AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. View Presentation Latest News View all news Upcoming Events View All Events Innovation. TeamOur team Technology Our platformPartners Partner with us Capabilities Naturally-derived antibodies Multispecifics Single-domain antibodies T-cell engagers GPCRs & ion channels Infectious diseasesPlatform GPCRs & ion channels T-cell engagers Peptide-MHCs Science Our pipeline Our platform Our engine Resources Scientific case studies Presentations & posters Publications Partnership Partner with usNews & Events In the news Press kit Careers Work with us Current openings Contact us AbCellera 2215 Yukon Street Vancouver, BC V5Y 0A1 office: 604.559.9005Legal Privacy Policy Legal Privacy Policy© AbCellera Biologics Inc. - All...
investors.abcellera.com Whois
Domain Name: ABCELLERA.COM Registry Domain ID: 1753364070_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2022-09-12T12:38:31Z Creation Date: 2012-10-19T19:31:37Z Registry Expiry Date: 2024-10-19T19:31:37Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-1281.AWSDNS-32.ORG Name Server: NS-1669.AWSDNS-16.CO.UK Name Server: NS-3.AWSDNS-00.COM Name Server: NS-972.AWSDNS-57.NET DNSSEC: unsigned >>> Last update of whois database: 2024-05-18T07:33:31Z <<<